1,720,970 research outputs found

    sj-docx-1-tau-10.1177_17562872211053189 – Supplemental material for Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis

    No full text
    Supplemental material, sj-docx-1-tau-10.1177_17562872211053189 for Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis by Carlo Cattrini, Carlo Messina, Chiara Airoldi, Sebastiano Buti, Giandomenico Roviello, Alessia Mennitto, Orazio Caffo, Alessandra Gennari and Melissa Bersanelli in Therapeutic Advances in Urology</p

    sj-jpg-1-onc-10.1177_11795549211043427 – Supplemental material for Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study

    No full text
    Supplemental material, sj-jpg-1-onc-10.1177_11795549211043427 for Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study by Sebastiano Buti, Fabiana Perrone, Teresa Zielli, Giulia Mazzaschi, Chiara Casartelli, Alessandro Leonetti, Gianluca Milanese, Mario Silva, Roberta Eufrasia Ledda, Antonino Musolino, Francesca Pucci, Melissa Bersanelli and Marcello Tiseo in Clinical Medicine Insights: Oncology</p

    sj-docx-1-onc-10.1177_11795549211043427 – Supplemental material for Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study

    No full text
    Supplemental material, sj-docx-1-onc-10.1177_11795549211043427 for Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study by Sebastiano Buti, Fabiana Perrone, Teresa Zielli, Giulia Mazzaschi, Chiara Casartelli, Alessandro Leonetti, Gianluca Milanese, Mario Silva, Roberta Eufrasia Ledda, Antonino Musolino, Francesca Pucci, Melissa Bersanelli and Marcello Tiseo in Clinical Medicine Insights: Oncology</p

    Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma

    No full text
    : For years, prospective randomized clinical trials excluded patients with non-conventional histologies of renal cell carcinoma (RCC). The paucity of data has led to adopting the same treatment strategies used for clear-cell RCC (ccRCC). In the present narrative review, we explored state of the art about use of immune checkpoint inhibitors (ICIs) in variant histologies of RCC. According to the results collected, ICIs as monotherapy showed promising antitumor activity in advanced non-clear cell (ncc)RCC. The objective response rate (ORR) was similar to that observed with single-agent anti-PD-1 in the ccRCC population, either in the first-line or the second-line setting, and responder patients experienced an early and durable benefit. Combined ICI-based strategies have shown increasing evidence in nccRCC and robust results in the sarcomatoid variants of RCC. A definitive recommendation about treating non-conventional histologies, either in adjuvant or metastatic settings, should be supported by more extensive dedicated trials

    sj-pdf-1-tau-10.1177_17562872241244574 – Supplemental material for Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients

    No full text
    Supplemental material, sj-pdf-1-tau-10.1177_17562872241244574 for Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients by Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari and Melissa Bersanelli in Therapeutic Advances in Urology</p

    sj-docx-1-tau-10.1177_17562872241244574 – Supplemental material for Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients

    No full text
    Supplemental material, sj-docx-1-tau-10.1177_17562872241244574 for Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients by Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari and Melissa Bersanelli in Therapeutic Advances in Urology</p

    Going Beyond Counting First Authors in Author Co-citation Analysis

    Full text link
    The present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed

    Variations on the Author

    Full text link
    “Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship

    Appropriate Similarity Measures for Author Cocitation Analysis

    Full text link
    We provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
    corecore